Related Experiment Video
Updated: Jun 9, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
[Pulmonary hypertension - historical development, current therapy and perspectives].
1Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover. hoeper.marius@mh-hannover.de
The history of pulmonary hypertension spans from late 19th-century lesion descriptions to mid-20th-century catheterization enabling clinical study. Intravenous prostacyclin, introduced in 1980, marked the first effective treatment for pulmonary hypertension.
Area of Science:
- Cardiovascular Medicine
- Pulmonology
- Medical History
Context:
- Pulmonary hypertension (PH) has a long history of study, with early descriptions of vascular lesions in the late 19th century.
- Histopathological changes were documented in the first half of the 20th century, but clinical understanding was limited.
- The development of right ventricular and pulmonary artery catheterization in the mid-20th century revolutionized the study of PH.
Purpose:
- To provide a historical overview of pulmonary hypertension.
- To trace the evolution of understanding its pathogenesis and clinical manifestations.
- To highlight key milestones in the diagnosis and treatment of pulmonary hypertension.
Summary:
- Early research focused on histopathology, with significant advancements in clinical study following the advent of cardiac catheterization.
- Initial therapeutic interventions, such as vasodilators, proved unsuccessful.
- Intravenous prostacyclin emerged as the first effective treatment in 1980, significantly improving outcomes for some PH forms.
- Despite progress, much remains unknown, and a universal cure for pulmonary hypertension is not yet available.
Impact:
- Catalyzed the development of diagnostic techniques for pulmonary hypertension.
- Paved the way for the discovery of the first effective treatments for pulmonary hypertension.
- Established a foundation for ongoing research into the complex pathogenesis and treatment of pulmonary hypertension.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

